Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Plby Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.54 (market cap $9.43B), while Plby Group Inc trades at $1.27 (market cap $162.94M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 57.9× Plby Group Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PLBY | |
|---|---|---|
Market Cap | $9.43B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $2.71 |
52-Week Low | $241.71 | $1.11 |
Enterprise Value | $9.18B | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
PLBY trades at $1.28, up 8.47% in the last session, with a bullish technical signal from moving averages. The company shows improving fundamentals, with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains slim at 0.23%. Recent news highlights inclusion in the Russell 2000 index and a share repurchase program.
The outlook is cautiously optimistic, supported by analyst consensus and positive cash flow trends, but high debt levels and inconsistent earnings history pose risks. Investment opportunity lies in brand licensing growth, while execution and competitive pressures are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
